Armpit Thermometers Helped Spread Fungus at UK Hospital
Armpit thermometers led to a large outbreak of drug-resistant Candida auris fungus in the United Kingdom. (Source: WebMD Health)
Source: WebMD Health - May 4, 2018 Category: Consumer Health News Source Type: news

Armpit Thermometers Helped Spread Dangerous Fungus at UK Hospital
FRIDAY, May 4, 2018 -- Armpit thermometers led to a large outbreak of drug-resistant Candida auris fungus in the United Kingdom, researchers say. The outbreak occurred in Oxford University Hospitals'neurosciences intensive care unit. The culprit:... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 4, 2018 Category: General Medicine Source Type: news

Monash study exposes key tactic used by deadly fungus
(Monash University) Associate Professor Ana Traven, in collaboration with the Naderer lab, has found that a lethal fungus destroys the immune cell that would ordinarily kill it, by stealing its source of nutrients. Candida albicans is a microscopic fungus commonly found in the body but which can become a dangerous infection in vulnerable hospital patients. The study demonstrated that the fungus competes with disease-fighting macrophages by rapidly consuming glucose and causing the macrophages to die. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 1, 2018 Category: Biology Source Type: news

FDA Clears First Test for Emerging Pathogen Candida auris FDA Clears First Test for Emerging Pathogen Candida auris
The Bruker Maldi Biotyper CA system can reliably identify C auris 100% of the time.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 23, 2018 Category: Consumer Health News Tags: Infectious Diseases News Alert Source Type: news

Sharing thermometers in hospital spreads Japanese fungus in wards
Shared thermometers used to measure armpit temperature are a likely source of Candida auris - a dangerous Japanese fungus which has swept through British hospital wards, experts believe. (Source: the Mail online | Health)
Source: the Mail online | Health - April 21, 2018 Category: Consumer Health News Source Type: news

FDA authorizes new use of test, first to identify the emerging pathogen < i > Candida auris < /i >
FDA authorized the first test to identify the emerging pathogen Candida auris, which can cause serious infections in hospitalized patients. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 20, 2018 Category: American Health Source Type: news

Large Candida auris outbreak linked to multi-use thermometers in UK ICU
(European Society of Clinical Microbiology and Infectious Diseases) Outbreaks of the fungal pathogen Candida auris in healthcare settings, particularly in intensive care units (ICUs), may be linked to multi-use patient equipment, such as thermometers, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 20, 2018 Category: Biology Source Type: news

Notes from the Field: Surveillance for Candida auris — Colombia, September 2016–May 2017
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - April 19, 2018 Category: American Health Source Type: news

Activity of Ceragenin CSA-131 against Candida Auris
Published Research Shows Ceragenin CSA-131 ’s Potent Efficacy against Candidaauris, a New Serious Global Health ThreatDUBLIN, OHIO – April 5, 2018 – N8 Medical, LLC today announced a peer-reviewed publication in The Journal ofAntimicrobial Chemotherapy with U.S. Centers for Disease Control and Prevention (CDC) co-authors of promisingefficacy data regarding the activity of ceragenin CSA-131 against 100 strains of Candida auris (C. auris) collected fromaround the world. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - April 9, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Microscopic revelations point to new blood infection therapies
(University of Calgary) Researchers at the University of Calgary's Cumming School of Medicine (CSM) have for the first time been able to observe -- live and in real-time -- how the human body responds to often lethal fungal blood infections in the lung. In the study, the fungal infection Candida albicans was introduced to mice or human models of the lung vasculature and as blood was pumped over that system, researchers recorded what happened using highly sophisticated microscopes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 4, 2018 Category: International Medicine & Public Health Source Type: news

T2 Biosystems touts results from 4 studies of its T2Dx diagnostics system
T2 Biosystems this week released results from four studies of its T2Dx blood diagnostics system designed to detect pathogens that cause sepsis, touting clinical and performance advantages when compared to traditional blood cultures. The four studies were published in the Journal of Antimicrobial Chemotherapy, the Lexington, Mass.-based company said. A study conducted at Rome’s Gemelli Hospital examined the use of the T2Bacteria panel on the T2Dx, and found that positive results were produced 4.5 times faster at 5.5 hours versus 25 hours with a standard blood culture. Negative results on the T2Bacteria panel were...
Source: Mass Device - March 30, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Diagnostics T2 Biosystems Inc. Source Type: news

Amplyx Pharmaceuticals Receives Fourth "Qualified Infectious Disease Product" (QIDP) Designation from the FDA for APX001
QIDP Designation Granted for Treatment of Cryptococcosis Provides Priority Review, Fast-Track Status and Five Additional Years of Market Exclusivity SAN DIEGO, March 19, 2018 -- (Healthcare Sales & Marketing Network) -- Amplyx Pharmaceuticals, a compan... Biopharmaceuticals, FDA Amplyx Pharmaceuticals, Candida, Aspergillus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 19, 2018 Category: Pharmaceuticals Source Type: news

Plant-derived volatiles may serve as future antifungals
(VIB (the Flanders Institute for Biotechnology)) A research team at the VIB-KU Leuven Center for Microbiology has developed a novel screening method to identify antimicrobial properties of volatile substances. With this assay, they tested the vapour-phase-mediated activity of 175 essential oils (EOs) and 37 EO components. Approximately half of them proved active against the most drug-resistant type of Candida. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 9, 2018 Category: Biology Source Type: news

T2 Biosystems tops The Street with Q4, 2017 earnings
T2 Biosystems Inc. (NSDQ:TTOO) today reported fourth quarter and full year 2017 earnings that topped expectations on Wall Street. The Lexington, Mass.-based company reported sales of $1.7 million for its fourth quarter, up 87% when compared with the same quarter least year. Costs for the quarter, excluding the cost of product revenue, were $9.8 million, down 16% over the previous years costs and expenses. Sales expectations for the fourth quarter on Wall Street were $1.3 million, which the company handily topped. For the full year, T2 Biosystems reported revenue of $4.7 million, up 15% from the previous year. Product ...
Source: Mass Device - March 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat T2 Biosystems Inc. Source Type: news

Is a high sugar diet damaging your gut? Six signs you could have candida overgrowth
CANDIDA is a yeast that naturally exists in the mouth, gut and vagina. It isn ’t a problem until it grows and overpopulates your digestive system, which can a number of symptoms. Here are six signs you could have candida overgrowth syndrome. (Source: Daily Express - Health)
Source: Daily Express - Health - February 16, 2018 Category: Consumer Health News Source Type: news

Could a Rare, Deadly ‘ Superbug ’ Fungus Be Gaining a Foothold? Could a Rare, Deadly ‘ Superbug ’ Fungus Be Gaining a Foothold?
The Centers for Disease Control and Prevention says the number of confirmed cases of Candida auris in the U.S. has climbed from seven in 2016 to at least 200.Kaiser Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2018 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

WPI Biologist Reeta Rao elected a fellow of the American Academy of Microbiology
(Worcester Polytechnic Institute) Reeta Rao, a biologist at Worcester Polytechnic Institute (WPI), has been elected a fellow of the American Academy of Microbiology. She studies the biology of fungal diseases, particularly those caused by Candida, a species of fungi responsible for oral thrush, ear infections, and vaginitis, but which is also the leading cause of serious illnesses among hospitalized patients. Treating these life-threatening infections, which have a 30-50 percent mortality rate, costs more than $1 billion annually. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 31, 2018 Category: International Medicine & Public Health Source Type: news

Emerging Multidrug-Resistant Candida Species Emerging Multidrug-Resistant Candida Species
Infections caused by multidrug-resistant Candida species are on the rise. How are these infections best treated?Current Opinion in Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2018 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

New antifungal provides hope in fight against superbugs
(Case Western Reserve University) Microscopic yeast have been wreaking havoc in hospitals around the world -- creeping into catheters, ventilator tubes, and IV lines -- and causing deadly invasive infection. One culprit species, Candida auris, is resistant to many antifungals, meaning once a person is infected, there are limited treatment options. But in a recent Antimicrobial Agents and Chemotherapy study, researchers confirmed a new drug compound kills drug-resistant C. auris, both in the laboratory and in a mouse model that mimics human infection. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 11, 2018 Category: Infectious Diseases Source Type: news

PROBIOTICS as medicine: Proper yeast balance in the gut microbiome found to help schizophrenia sufferers
(Natural News) Schizophrenia is a psychiatric disorder wherein a person displays abnormal social behavior and a failure to differentiate between reality and fantasy. More often than not, schizophrenic individuals have yeast infections, but researchers still do not know why. These yeast infections, caused by Candida albicans found in human gut flora, do not cause mental... (Source: NaturalNews.com)
Source: NaturalNews.com - December 10, 2017 Category: Consumer Health News Source Type: news

The mouth is a first responder for the immune system: New study provides clues for how the body defends against oral invaders
(Natural News) New research has identified how the mouth acts as a trigger for the immune system’s defenses to kick in once the fungus Candida albicans – which causes oral thrush –  has invaded the body. The international team, led by the researchers at the University of Pittsburgh School of Medicine, studied how microbes inside the mouth called commensals,... (Source: NaturalNews.com)
Source: NaturalNews.com - December 5, 2017 Category: Consumer Health News Source Type: news

Preclinical Evaluation of the Stability, Safety and Efficacy of CD101, a Novel Echinocandin
Fungal infections pose a significant public health burden with high morbidity and mortality. CD101 is a novel echinocandin under development for the treatment and prevention of systemic Candida infections. Preclinical studies were conducted to evaluate the metabolic stability, plasma protein binding, pharmacokinetics, toxicity, and efficacy of CD101 at various dose levels. CD101 was stable to biotransformation in rat/monkey/human liver microsomes and rat/monkey/dog/human hepatocytes. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 1, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Novel Macrocyclic Amidinoureas: Potent Non-Azole Antifungals Active against Wild-Type and Resistant Candida Species
Novelmacrocyclic amidinourea derivatives 11, 18, and 25 were synthesized and evaluated as antifungal agentsagainstwild-type and fluconazoleresistantCandidaspecies. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 20, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.
MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of β-(1,3)-glucan. We evaluated the invitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene(s) of Candida spp. and Aspergillus spp.MK-3118 demonstrated enhanced efficacy for most C. albicans and C. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 20, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Antifungal activity of statins against Aspergillus species
The cholesterol-lowering agents known as statins have in vitro activities against human pathogenic fungi, such as Candida species, Cryptococcus neoformans, and Zygomycetes. Synergy between statins and azoles against these fungi has also been reported. We evaluated the in vitro activities of two statins, lovastatin andsimvastatin, alone and in combination with azoles and amphotericin B, against clinical isolates ofAspergillus spp. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Growth inhibition of Candida species and Aspergillus fumigatus by statins.
Statins are a class of drugs widely used for lowering high cholesterol levels through their action on 3-hydroxy-3-methylglutaryl-CoA reductase, a key enzyme in the synthesis of cholesterol. We studied the effects of two major statins,simvastatin and atorvastatin, on five Candida species andAspergillus fumigatus. The statins strongly inhibited the growth of all species, except Candida krusei. Supplementation of Candida albicans and A. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Antifungal spectrum, in vivo efficacy, and structure-activity relationship of ilicicolin H
Ilicicolin H is a polyketide-nonribosomal peptide synthase (NRPS)-natural product isolated from Gliocadium roseum, which exhibits potent and broad spectrum antifungal activity, with sub- μg/mL MICs against Candida spp., Aspergillus fumigatus, and Cryptococcus spp. It showed a novel mode of action, potent inhibition (IC50 = 2-3 ng/mL) of the mitochondrial cytochrome bc1 reductase, and over 1000-fold selectivity relative to rat liver cytochrome bc1 reductase. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice
The activities ofR-135853, a novel sordarin derivative that possesses a 1,4-oxazepane ring moiety, were evaluated in vitro and in vivo.R-135853 exhibited potent in vitro activities against Candida albicans (fluconazole-susceptible strains), Candida glabrata, Candida tropicalis, and Cryptococcus neoformans, with MICs at which 90% of isolates were inhibited of 0.03, 1, 0.5, and 0.5 microg/ml, respectively. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

In Vitro and In Vivo Activity of a Novel Antifungal Small Molecule against Candida Infections
Candida is the most common fungal pathogen of humans worldwide and has become a major clinical problem because of the growing number of immunocompromised patients, who are susceptible to infection. Moreover, the number of available antifungals is limited, and antifungal-resistantCandida strains are emerging. New and effective antifungals are therefore urgently needed. Here, we discovered a small molecule with activity againstCandida spp. bothin vitro andin vivo. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Drugs in Clinical Development for Fungal Infections (includes MAT023, encochleated amphotericin B))
Despite increasing rates of invasive fungal infections being reported globally, only a single antifungal drug has been approved during the last decade. Resistance, toxicity, drug interactions and restricted routes of administration remain unresolved issues. This review focuses on new antifungal compounds which are currently in various clinical phases of development. We discuss two azoles with a tetrazole moiety that allows selective activity against the fungal CYP: VT-1161 for Candida infections and VT-1129 for cryptococcal meningoencephalitis. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition
The synthesis and antifungal activity ofASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition and significantly improved MIC against Candida parapsilosis and echinocandin resistant-Candida is described. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

FR290581, a novel sordarin derivative: synthesis and antifungal activity
Sordarin is a unique natural product antifungal agent that is an inhibitor of elongation factor 2. To improve biological activity, we synthesized various compounds by novel modification of the aglycone, sordaricin. As a result, we have discovered the novel sordarin derivativeFR290581. This compound exhibited superior activity and a good pharmacokinetic profile, and also displayed good in vivo activity against Candida albicans. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Correlation between In Vitro and In Vivo Activities of GM 237354, a New Sordarin Derivative, against Candida albicans in an In Vitro Pharmacokinetic-Pharmacodynamic Model and Influence of Protein Binding
The antifungal effect ofGM 237354, a sordarin derivative, was studied in an in vitro pharmacokinetic (PK)-pharmacodynamic dynamic system (bioreactor) which reproduces PK profiles observed in a previously described model of drug efficacy against murine systemic candidiasis. Immunocompetent mice infected intravenously with 10(5) CFU of Candida albicans were treated withGM 237354 at 2.5, 10, and 40 mg/kg of body weight every 8 h subcutaneously for 7 days. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

CDC Updates Guidance as Candida auris Cases Grow CDC Updates Guidance as Candida auris Cases Grow
Cases of the deadly yeast have increased exponentially in the past year in the US, leading the Centers for Disease Control and Prevention to recommend that labs identify species when Candida is found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 5, 2017 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

' Fungal Superbug' Raising Fears
(MedPage Today) -- But few Candida auris cases so far in U.S. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 5, 2017 Category: Primary Care Source Type: news

Drugs in Clinical Development for Fungal Infections (review includes CD101)
Despite increasing rates of invasive fungal infections being reported globally, only a single antifungal drug has been approved during the last decade. Resistance, toxicity, drug interactions and restricted routes of administration remain unresolved issues. This review focuses on new antifungal compounds which are currently in various clinical phases of development. We discuss two azoles with a tetrazole moiety that allows selective activity against the fungal CYP: VT-1161 for Candida infections and VT-1129 for cryptococcal meningoencephalitis. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 5, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Novamycin (NP339)
Novamycin ® (NP339) is a novel antifungal peptide developed forfront-line treatment of medically unmet, yeast and mould infections, particularly those caused by Aspergillus spp. and Candida spp. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 5, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Candida Crewe reveals how she overcame nausea
After hearing of the Duchess of Cambridge's plight, journalist Candida Crewe details her own experience with debilitating nausea. (Source: the Mail online | Health)
Source: the Mail online | Health - September 25, 2017 Category: Consumer Health News Source Type: news

One writer reveals how she overcame nausea
After hearing of the Duchess of Cambridge's plight, journalist Candida Crewe details her own experience with debilitating nausea. (Source: the Mail online | Health)
Source: the Mail online | Health - September 25, 2017 Category: Consumer Health News Source Type: news

How BIOHM's At Home Candida Test Is Giving Consumers Peace of Mind
How the scientist that named the mycobiome is using a simple at home test to give consumers an easy way to analyze the Candida in their guts. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 16, 2017 Category: Pharmaceuticals Authors: Afif Ghannoum, Contributor Source Type: news

Tackling an Invasive, Emerging, Multi-Drug Resistant Yeast: Candida Auris - What Healthcare Providers Need to Know
Centers for Disease Control and Prevention. 08/15/2017 This one-hour webinar describes the epidemiology of Candida auris (C. auris), an emerging multi-drug-resistant fungus that can cause invasive infections with high mortality, and has been associated with outbreaks in healthcare settings. It explains the guidance for diagnosis and treatment of C. auris, and the infection control recommendations for containing C. auris. (Video or Multimedia) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - September 12, 2017 Category: International Medicine & Public Health Authors: The U.S. National Library of Medicine Source Type: news

T2 Biosystems files 510(k) for T2Bacteria Panel
T2 Biosystems Inc. (NSDQ:TTOO) said today it filed a 510(k) appliation with the FDA for its T2Bateria Panel rapid diagnostic solution designed to identify pathogens assocaited with Sepsis. The T2Bacteria panel is designed to run on the FDA-cleared T2Dx instrument to provide diagnosis of sepsis pathogens within hours, reducing the time for patients with bloodstream infections to receive treatment, the Lexington, Mass.-based company said. The submission includes data from a pivotal clinical trial of the T2Bacteria Panel which compared it to blood culture, as well as the performance of the panel in known bacteria positiv...
Source: Mass Device - September 11, 2017 Category: Medical Devices Authors: Fink Densford Tags: Diagnostics Food & Drug Administration (FDA) Regulatory/Compliance T2 Biosystems Inc. Source Type: news

MassDevice.com +5 | The top 5 medtech stories for September 7, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Heraeus Medical Components acquires Biotectix Heraeus Medical Components is acquiring conductive polymer materials maker Biotectix. The deal, announced yesterday, will allow Heraeus to boost its medical electrode coating capabil...
Source: Mass Device - September 7, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

CDC to use T2 Biosystems in testing for superbug Candida auris
T2 Biosystems Inc. (NSDQ:TTOO) said today that the US Centers for Disease Control and Prevention will use its T2Dx Instrument to test and monitor for the emergence and outbreaks of the antibiotic-resistant superbug Candida auris. The Lexington, Mass.-based company said the use of the T2Dx “represents multiple, new applications” for the platform. The system will be used for the 1st time to test patient skin and blood samples and also for environmental surveillance and to monitor outbreaks. Both applications are currently available as research tools for investigational purposes in the US and Europe, T2 Biosy...
Source: Mass Device - September 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Diagnostics T2 Biosystems Inc. Source Type: news

Candida cleanse diet: What does it treat?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - September 6, 2017 Category: Consumer Health News Source Type: news

Candida Auris: A New Fungal Superbug Emerging As A Global Threat
For the first time, a new yeast, Candida auris, is found to be spreading from person to person in hospitals. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 24, 2017 Category: Pharmaceuticals Authors: Judy Stone, Contributor Tags: NYSE:PFE NYSE:MRK Source Type: news

The Unexpected and Troubling Rise of Candida auris The Unexpected and Troubling Rise of Candida auris
Behaving like a multidrug-resistant microbe, C auris is spreading rapidly throughout the world, including in healthcare facilities in the United States.CDC Expert Commentary (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2017 Category: Consumer Health News Tags: Infectious Diseases Commentary Source Type: news

IBS warning: Bloating and stomach pain could actually be too much of THIS
IBS - or irritable bowel syndrome - is a common digestive condition causing stomach pain and bloating. However, symptoms could actually be triggered by an overgrowth of a yeast called candida. (Source: Daily Express - Health)
Source: Daily Express - Health - August 22, 2017 Category: Consumer Health News Source Type: news

Trust distances itself from staffing link to fungus outbreak
A major London hospital trust has sought to distance itself from suggestions that a lack of nursing staff was implicit in an outbreak of the so-called “Japanese fungus” infection Candida auris. (Source: Nursing Times)
Source: Nursing Times - August 17, 2017 Category: Nursing Source Type: news

Lack of nurses blamed for the spread of Japanese fungus
King's College Hospital in South London was responsible for 31 cases of Candida auris fungus infections during a year-long outbreak, figures show. Bosses at its trust blamed a lack of nurses. (Source: the Mail online | Health)
Source: the Mail online | Health - August 16, 2017 Category: Consumer Health News Source Type: news